APLN and systemic sclerosis: The Lafyatis laboratory used scRNA‐seq to gain insights into vasculopathy of systemic sclerosis (SSc) by characterizing cutaneous endothelial cells and revealed genes APLNR and HSPG2, which are mediators of Apelin/Elabela‐APLNR and TGF‐β signalling and could potentially serve as biomarkers of pathogenesis.54